Clinical Trial Update: Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months

View source ↗

Summary

This document reports a completed observational study evaluating NovoMix 50 for the treatment of Type 2 diabetes mellitus over 12 months.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoMix 50 (biphasic insulin aspart 50)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Status: COMPLETED